Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

被引:39
作者
Lopez-Ruiz, Alfonso [1 ]
del Peso-Gilsanz, Cristina [1 ]
Meoro-Aviles, Amparo [1 ]
Soriano-Palao, Jose [1 ]
Andreu, Alberto [1 ]
Cabezuelo, Juan [1 ]
Arias, Jose L. [2 ]
机构
[1] Reina Sofia Univ Hosp, Diabet Unit, Murcia 30003, Spain
[2] Univ Granada, Dept Pharm & Pharmaceut Technol, E-18071 Granada, Spain
来源
PHARMACY WORLD & SCIENCE | 2010年 / 32卷 / 05期
关键词
Adverse drug effect; ADE; Angiotensin II receptor antagonist; Candesartan; Combined therapy; Diuretic; Exenatide; Hydrochlorothiazide; Ischemic acute renal failure; Renal function; Type 2 diabetes mellitus; GLUCOSE; WEIGHT;
D O I
10.1007/s11096-010-9423-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Case (description) the patient is a 20 years old male smoker, who was diagnosed with type 2 diabetes mellitus in 2006. Due to the inadequate response to the previously established treatment, the pharmacotherapy was modified by introducing exenatide (up to 10 mu g, twice daily) instead of insulin glargine, but maintaining the treatment with the diuretic and angiotensin II receptor antagonist drugs. Two months later, the patient exhibited a very important intolerance to exenatide (continuous nausea, vomiting, and dehydration), finally leading to ischemic acute renal failure. When the angiotensin II receptor antagonist and exenatide were suspended, a very rapid recovery of renal function was observed. Conclusion ischemic acute renal failure is supposed to be the consequence of the extracellular volume contraction caused by exenatide (the result of continuous nausea and vomiting). This adverse effect could be caused by the co-administration of diuretics and angiotensin II receptor antagonists.
引用
收藏
页码:559 / 561
页数:3
相关论文
共 10 条
[1]   One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial [J].
Bunck, Mathijs C. ;
Diamant, Michaela ;
Corner, Anja ;
Eliasson, Bjorn ;
Malloy, Jaret L. ;
Shaginian, Rimma M. ;
Deng, Wei ;
Kendall, David M. ;
Taskinen, Marja-Riitta ;
Smith, Ulf ;
Yki-Jarvinen, Hannele ;
Heine, Robert J. .
DIABETES CARE, 2009, 32 (05) :762-768
[2]   Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers [J].
Edwards, CMB ;
Stanley, SA ;
Davis, R ;
Brynes, AE ;
Frost, GS ;
Seal, LJ ;
Ghatei, MA ;
Bloom, SR .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 281 (01) :E155-E161
[3]   Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes [J].
Fineman, MS ;
Bicsak, TA ;
Shen, LZ ;
Taylor, K ;
Gaines, E ;
Varns, A ;
Kim, D ;
Baron, AD .
DIABETES CARE, 2003, 26 (08) :2370-2377
[4]   Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis [J].
Glass, Leonard C. ;
Qu, Yongming ;
Lenox, Sheila ;
Kim, Dennis ;
Gates, Jeffrey R. ;
Brodows, Robert ;
Trautmann, Michael ;
Bergenstal, Richard M. .
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (03) :639-644
[5]   Exenatide may aggravate moderate diabetic renal impairment: a case report [J].
Johansen, Odd Erik ;
Whitfield, Rolf .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (04) :568-569
[6]   Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use [J].
Kendall, David M. ;
Cuddihy, Robert M. ;
Bergenstal, Richard M. .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2009, 20 :S329-S339
[7]   Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes [J].
Kim, Dennis ;
MacConell, Leigh ;
Zhuang, Dongliang ;
Kothare, Prajakti A. ;
Trautmann, Michael ;
Fineman, Mark ;
Taylor, Kristin .
DIABETES CARE, 2007, 30 (06) :1487-1493
[8]   Synthetic exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes [J].
Kolterman, OG ;
Buse, JB ;
Fineman, MS ;
Gaines, E ;
Heintz, S ;
Bicsak, TA ;
Taylor, K ;
Kim, D ;
Aisporna, M ;
Wang, Y ;
Baron, AD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (07) :3082-3089
[9]   Exenatide efficacy and safety: a systematic review [J].
Norris, S. L. ;
Lee, N. ;
Thakurta, S. ;
Chan, B. K. S. .
DIABETIC MEDICINE, 2009, 26 (09) :837-846
[10]  
Weise Wolfgang J, 2009, Diabetes Care, V32, pe22, DOI 10.2337/dc08-1309